BioSpace News Archive

LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the market close.

MaxCyte, Inc. announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares of MaxCyte’s common stock to eight newly hired employees.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of cumulative 5-year results from two Phase 3 studies (Study 1489 and Study 1490) of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF).

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from an interim analysis of its ongoing, Phase 2/3 single arm, open-label study to evaluate the safety, tolerability and pharmacokinetics of Veklury® (remdesivir) in pediatric patients hospitalized with COVID-19 with ages ranging from 28 days to less than 18 years.

Stealth BioTherapeutics Corp announced that on February 11, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is currently not in compliance with the minimum Market Value of Publicly Held Shares requirement based upon Nasdaq’s review of the Company’s MVPHS for the 30 consecutive business days through February 10, 2022.

The United States Pathology and Laboratory Society Leadership has endorsed the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Joint Task Force recommendation to use a new race-free equation to diagnose kidney diseases, also known as chronic kidney disease.

Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), today announced that revenues for the year ended October 31, 2021 were approximately $20.1 million, a decrease of approximately $1.4 million when compared to last year.

Anika Therapeutics, Inc. announced that on February 1, 2022, Anika granted non-statutory stock options covering an aggregate of 10,428 shares of common stock and restricted stock units covering an aggregate of 4,699 shares of common stock to 3 newly hired non-executive employees.